Haemonetics Corporation
NYSE:HAEMedical - Instruments & Supplies
+$0.84 today
- Market cap
- $5.59B
- Beta
- 0.54
- P/E (TTM)
- 34.9
- EPS (TTM)
- $2.11
Volume 0.48M
Average 0.88M
HAE Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
Haemonetics CorporationNYSE: HAE
Research & Development · Q1 FY2027 · quarter ended Jun 2026
Research & development declines year over year
Q1 FY2027 research & development of $16.2M fell 0.4% year over year, ahead of the -4.4% change in trailing-twelve-month research & development. Sequentially, it rose 12.1% from the prior quarter. Over 3 fiscal years it compounded at +0.6% a year.
Context
- Research & development amounted to 4.5% of revenue in FY2026, down 0.6 pp from a year earlier.
- Research & development increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly growth of -0.4% holds above the trailing-twelve-month pace of -4.4%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2026
- 59.77M USD
- Year-over-year change
- -13.9%
- 4-year CAGR
- +2.0%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2026 | 2026-03-28 | 59.77M | -13.9% |
| FY2025 | 2025-03-29 | 69.42M | +10.1% |
| FY2024 | 2024-03-31 | 63.04M | +7.5% |
| FY2023 | 2023-03-31 | 58.63M | +6.2% |
| FY2022 | 2022-03-31 | 55.2M | — |
Research & Development vs competitors
How HAE compares with its peers on the latest reported figures
- HAE's LTM Jun 2026 research & development of $59.46M is the 5th highest of the 10 companies compared; the peer median is $48.58M.
- Its year-over-year change of -4.4% is the 4th highest of 8, against a peer median of -4.7%.
- Research & development amounts to 4.4% of revenue for HAE, versus a peer median of 4.3%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $634M | +1.3% | +5.9% | 5.8% | |
| LTM Jun 2026 | $408.66M | +3.1% | +9.5% | 261.9% | |
| LTM Mar 2026 | $177.9M | -16.4% | -0.3% | 6.7% | |
| LTM Mar 2026 | $158M | -0.6% | -4.8% | 4.3% | |
| LTM Jun 2026 | $59.46M | -4.4% | +0.6% | 4.4% | |
| LTM Jul 2026 | $48.58M | -4.7% | -8.1% | 2.6% | |
| LTM Mar 2026 | $14.1M | -9.9% | +2.1% | 5.5% | |
| LTM Mar 2026 | $11.48M | -17.7% | -13.7% | 1.9% | |
CONConcentra Group Holdings Parent, Inc. | LTM Sep 2026 | $0 | — | — | 0.0% |
| LTM Jun 2026 | $0 | — | — | 0.0% | |
| Peer median (excluding HAE) | $48.58M | -4.7% | -0.3% | 4.3% | |
Competitors are the stored peer set for HAE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2022 Mar 2022 | FY2023 Mar 2023 | FY2024 Mar 2024 | FY2025 Mar 2025 | FY2026 Mar 2026 |
|---|---|---|---|---|---|
| Revenue | 993.2M | 1.17B | 1.31B | 1.36B | 1.33B |
| Cost of Revenue | 462.43M | 545.79M | 597.14M | 582.28M | 590.44M |
| Gross Profit | 530.77M | 622.87M | 711.92M | 778.55M | 743.59M |
| Gross Margin | 53.4% | 53.3% | 54.4% | 57.2% | 55.7% |
| Research & Development | 55.2M | 58.63M | 63.04M | 69.42M | 59.77M |
| Selling, General & Admin | 332.2M | 373.95M | 420.82M | 422.05M | 442.42M |
| Operating Expenses | 450.02M | 466.84M | 547.03M | 556.73M | 502.19M |
| Depreciation & Amortization | 97.75M | 93.31M | 97.22M | 115.59M | 111.72M |
| EBITDA | 202.92M | 260.51M | 304.05M | 362.69M | 268.45M |
| EBITDA Margin | 20.4% | 22.3% | 23.2% | 26.7% | 20.1% |
| Operating Income | 80.75M | 156.03M | 164.88M | 221.82M | 241.4M |
| Operating Margin | 8.1% | 13.4% | 12.6% | 16.3% | 18.1% |
| Interest Income | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 17.12M | 14.63M | 13.02M | 9.75M | 28.7M |
| Other Income / Expenses | (17.12M) | (14.63M) | (13.02M) | (9.75M) | (113.37M) |
| Income Before Tax | 63.63M | 141.4M | 151.87M | 212.07M | 128.03M |
| Pre-Tax Margin | 6.4% | 12.1% | 11.6% | 15.6% | 9.6% |
| Income Tax Expense | 20.25M | 26M | 34.31M | 44.39M | 30.72M |
| Net Income | 43.38M | 115.4M | 117.56M | 167.68M | 97.31M |
| Net Margin | 4.4% | 9.9% | 9.0% | 12.3% | 7.3% |
| EPS (Basic) | 0.85 | 2.27 | 2.32 | 3.31 | 2.05 |
| EPS (Diluted) | 0.84 | 2.24 | 2.29 | 3.31 | 2.05 |
| Weighted Avg Shares | 51.05M | 50.78M | 50.71M | 50.33M | 47.18M |
| Weighted Avg Shares (Diluted) | 51.35M | 51.42M | 51.4M | 50.73M | 47.35M |
Haemonetics Corporation
NYSE:HAE
Intrinsic Alpha fair value
Locked
Current Price
$122.86
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.